Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Linking Postoperative Pain, GCF NLRP3 , and Treatment Success Following MTA Full Pulpotomy Vs Root Canal Treatment in Symptomatic Irreversible Pulpitis (NLRP3)

14 de noviembre de 2026 actualizado por: Bassant Yasser Shaker Ibrahim El-Saharty, Cairo University

Linking Postoperative Pain, GCF NLRP-3 Dynamics, and Treatment Success Following MTA Full Pulpotomy Versus Root Canal Treatment in Symptomatic Irreversible Pulpitis : A Randomized Clinical Trial

To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Descripción general del estudio

Descripción detallada

Aim: To compare MTA full pulpotomy with conventional non-surgical root canal treatment in mature mandibular permanent molars with symptomatic irreversible pulpitis. The comparison covers postoperative pain, analgesic consumption, change in GCF NLRP3 levels, and clinical and radiographic success. A further aim is to assess whether changes in GCF NLRP3 are related to pain and to success.

Methods: This is a two-arm, parallel, assessor-blinded, randomized trial conducted at the Endodontic clinic, Faculty of Dentistry, Cairo University. Sixty patients with a periapical index score ≤ 2 will be randomized to receive either full pulpotomy with MTA or single-visit root canal treatment (n=30 per group). The primary outcome is postoperative pain at 24 hours on an 11-point Numerical Rating Scale. Secondary outcomes are:

pain at 6, 12, 48 and 72 hours and on day 7; number of ibuprofen 400 mg tablets taken over 7 days; GCF NLRP3 levels measured by ELISA preoperatively from tooth and healthy contralateral (internal control) and on day 7 from tooth; clinical and radiographic success at 6 and 12 months.

Analysis will follow the intention-to-treat principle, using the independent-samples t-test or Mann-Whitney U test, the chi-square or Fisher's exact test, and Spearman's rank correlation, with significance set at P ≤ 0.05.

Expected significance: The trial will show whether a simpler, pulp-preserving procedure offers pain and success outcomes comparable to root canal treatment, and whether GCF NLRP3 can serve as a chairside biomarker of healing.

Keywords: symptomatic irreversible pulpitis; full pulpotomy; mineral trioxide aggregate; root canal treatment; postoperative pain; NLRP3 inflammasome; gingival crevicular fluid

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Giza Governorate
      • Al Manyal, Giza Governorate, Egipto
        • Cairo University
        • Contacto:
        • Contacto:
        • Sub-Investigador:
          • lubna shafie, professor

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 40 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients 18-40 years old.
  • Male or female
  • Mandibular molars with SIP: preoperative sharp, moderate or severe pain, with normal periapical radiographic appearance or slight widening(PAI ≤ 2)
  • Systemically healthy (ASA I) or controlled disease (ASA II)
  • Able to understand NRS and sign informed consent
  • Good oral hygiene, with no plaque or calculus, no bleeding on probing (BOP

Exclusion Criteria:

  • Medically compromised patients with significant systemic disorders (ASA III or IV)
  • History of intolerance to NSAIDs/ Use of ibuprofen in the last 12 hours
  • Two or more adjacent teeth requiring endodontic treatment
  • External or internal root resorption
  • Vertical root fracture
  • Periapical lesion
  • Controlled diabetes & smoking
  • Acute periapical abscess or acute exacerbation of a chronic abscess
  • Pregnancy
  • Long-term corticosteroid use
  • Mobility grade II or III
  • Previous root canal therapy
  • Non-restorability
  • TMJ problems, bruxism, clenching or traumatic occlusion
  • Inability to perceive given instructions
  • Antibiotic intake during the 10 days before treatment (may alter GCF inflammatory mediators)
  • Gingival bleeding (gingivitis), recession > 3 mm or pocketing at the GCF sampling sites of the study or contralateral tooth
  • Absent contralateral tooth, or one that is carious, deeply restored or endodontically treated (it is the GCF control)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Non-surgical root canal treatment

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points.

Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

6 Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Experimental: full pulpotomy with MTA

After caries removal and de-roofing, the entire coronal pulp is amputated to the canal orifices with a sterile sharp excavator; chamber rinsed with 2.5% NaOCl.

2 Haemostasis Cotton pellet soaked in 2.5% NaOCl on radicular stumps with light pressure for 2 min, then inspect; repeat up to 10 min in total. Achieved when no fresh bleeding comes from any orifice. Time to haemostasis (min) recorded.

3 Pulp capping & restoration MTAputty , 2-3 mm over stumps and chamber floor, adapted with a moist pellet. After 10 min: glass-ionomer layer, then bonded resin composite in same visit.

! If haemostasis is not achieved Bleeding not controlled within 10 min, or necrotic / non-bleeding radicular pulp → pulpectomy and RCT in the same visit (comparator protocol). Not withdrawn: recorded as a protocol deviation and counted as a pulpotomy failure (ITT); per-protocol sensitivity analysis excludes these cases.

Canals explored with k-file #08 & #10 hand files; WL with EAL, confirmed radiographically.

2 Irrigation 3 mL of 2.5% NaOCl after every instrument, side-vented needle placed 2 mm from the apex to limit apical extrusion.

3 Instrumentation Single visit; crown-down with DOTA rotary files; EDTA gel in continuous brushing motion.

4 Shaping sequence

  • 17/.08 (19 mm)→orifice opener
  • 17/.03→ rotary glide path
  • 20/.04, #25/.04, #30/.04 and #35/.04; canals dried with sterile paper points. 5 Obturation MC radiograph within 0.5-1 mm of radiographic apex; CLC with ADseal resin sealer.

Coronal seal & baseline film Same GIC base & bonded composite as pulpotomy group; immediate postoperativeradiograph

Otros nombres:
  • conventional root canal treatment

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
postoperative pain after 24 hours
Periodo de tiempo: 24 hours

using 11-point numeric rating scale (NRS) to score postoperative pain after 24 where 0 means no pain and 10 is worst imaginable pain

24 hours

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
postoperative pain after 6,12,48,72 and 7 days
Periodo de tiempo: 6, 12, 48,72 hours and 7 days

using 11-point numeric rating scale (NRS) to score postoperative pain after 6, 12, 48,72 hours and 7 days where 0 means no pain and 10 is worst imaginable pain.

6, 12, 48,72 hours and 7 days
GCF levels of NLRP3
Periodo de tiempo: preoperative and 7 days postoperative

using ELISA to detect levels of NLRP3 from gingival crevicular fluid

preoperative and 7 days postoperative
Clinical and radiographic success
Periodo de tiempo: 6 months

Evaluating clinical success ( absence of pain, swelling , sinus tract/ fistula, and tooth is functional) and radiographic success ( absence of periapical radiolucency, internal/ external resorption)

6 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • New ENDO 3.3.3-New ENDO 7.1.2

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir